Thus, SGLT2 inhibitors hold potential for mitigating inflammation, regulating endothelial dysfunction, and attenuating atherosclerosis, which are relevant to the pathophysiology of SLE. Here, SLC5A2 is linked to systemic lupus erythematosus.